Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

GSK Launches Discovery Fast Track Competition for Academic Researchers

Published: Wednesday, May 22, 2013
Last Updated: Wednesday, May 22, 2013
Bookmark and Share
Scientists in U.S., Canada challenged to submit groundbreaking research proposals for chance at collaborative partnership focused on drug discovery.

GlaxoSmithKline plc (GSK) announced the launch of Discovery Fast Track, a competition designed to accelerate the translation of academic research into novel therapies. Winners of the competition will partner with investigators on GSK’s Discovery Partnerships with Academia (DPAc) team with a goal of developing viable research-stage drug candidates into innovative medicines.

Launched in the U.K. in late 2010, the DPAc program is a new approach to drug discovery where academic partners become core members of drug-hunting teams. GSK and the academic partner share the risk and reward of innovation, where GSK funds activities in the partner laboratories, as well as provides in-kind resources to progress a program from an idea to a candidate medicine. DPAc’s reach is global. To date, GSK has initiated nine collaborations in nine disease areas, including two in the U.S. and one in Canada.

"DPAc programs are incredibly valuable,” said Roger Cone, professor of molecular physiology and biophysics at Vanderbilt University School of Medicine and a DPAc participant. “Pharmaceutical companies bring an industrial approach to drug discovery that can’t be replicated in academia. Combined with the pharmacological and biological expertise of academia, it’s a perfect combination of skills and resources."

To avoid initial contract negotiations, which are often perceived as the biggest bottleneck in the Pharma/academia collaborative process, the DPAc team conceived the Discovery Fast Track competition as a means to rapidly identify and screen the most promising hypotheses in academia.

“With the Discovery Fast Track competition, we want to give all academic researchers who are passionate about translating their science into therapy, a chance to collaborate and access GSK resources and expertise to help bring novel and transformative treatments to patients,” said Pearl Huang, Ph.D., Global Head of DPAc. “We are excited to receive submissions in all therapeutic areas and look forward to being part of the researcher’s journey in making a difference.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

GSK to Fully Acquire Cellzome for £61 Million
GSK to further expand its platform technology expertise with acquisition of chemical proteomics company.
Wednesday, May 16, 2012
Scientific News
Cell's Waste Disposal System Regulates Body Clock Proteins
New way to identify interacting proteins could identify potential drug targets.
Compound Doubles Up On Cancer Detection
Researchers have found that tagging a pair of markers found almost exclusively on a common brain cancer yields a cancer signal that is both more obvious and more specific to cancer.
Promising Drug Candidate to Treat Chronic Itch
In a new study, scientists from the Florida campus of The Scripps Research Institute (TSRI) describe a class of compounds with the potential to stop chronic itch without the adverse side effects normally associated with medicating the condition.
Are Changes to Current Colorectal Cancer Screening Guidelines Required?
Editorial suggests more research is needed to pinpoint age to end aggressive screening.
Assessing Cancer Patient Survival and Drug Sensitivity
RNA editing events another way to investigate biomarkers and therapy targets.
New Molecular Marker for Killer Cells
Cell marker enables prognosis about the course of infections.
Potential Target for Treatment of Autism
Grant of $2.4 million will support further research.
Sniffing Out Cancer
Scientists have been exploring new ways to “smell” signs of cancer by analyzing what’s in patients’ breath.
Inroads Against Leukaemia
Potential for halting disease in molecule isolated from sea sponges.
Molecular ‘Kiss Of Death’ Flags Pathogens For Destruction
Researchers have discovered that our bodies mark pathogen-containing vacuoles for destruction by using a molecule called ubiquitin, commonly known as the "kiss of death."

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos